Novartis ' generics subsidiary, Sandoz, has been withdrawn in the USA because of illegal price-fixing and other antitrust violations to account. The company had accepted a settlement in the amount of $ 195 million, announced the justice Department on Monday in Washington.

prosecutors had accused Sandoz, to years of conspiracy with competitors in the US generics market operated. "Sandoz has agreed for years with other manufacturers and their executives, in order to increase the prices for necessary drugs. The antitrust division will continue its ongoing investigations continue to draw both individuals and companies accountable," said Makan Delrahim, head of the antitrust Department of the Ministry of justice.

The company was accused of Manipulation of tenders and the fixing of prices of patent-free medicines, worth more than $ 500 million between 2013-2015.

to cooperate with The Novartis subsidiary said in a statement that the investigations by the US authorities. The managers of the affair are now employed by the company. (chk/sda)

Created: 03.03.2020, 05:14 PM